3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
8
Sarcoma
3
Gastrointestinal
3
Gynecologic
2
Genitourinary
2
Dermatologic
2
CNS
2
Breast
2
Other hematologic neoplasm
1
NET
1
Myeloid
1
Head & Neck
1
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
541
Precursor Cell Lymphoblastic Leukemia-Lymphoma
310
Hematologic Neoplasms
264
Leukemia
180
Myelodysplastic Syndromes
169
Leukemia, Lymphocytic, Chronic, B-Cell
168
Lymphoma
101
Lymphoma, Non-Hodgkin
94
Recurrence
84
Neoplasms
83
Multiple Myeloma
82
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
72
Leukemia, Myelomonocytic, Chronic
60
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
58
Burkitt Lymphoma
54
Leukemia, Biphenotypic, Acute
48
Myeloproliferative Disorders
45
Lymphoma, Follicular
43
Lymphoma, Mantle-Cell
42
Lymphoma, Large B-Cell, Diffuse
42
Hodgkin Disease
34
Lymphoma, B-Cell
32
Lymphoma, B-Cell, Marginal Zone
30
Leukemia, B-Cell
30
Anemia, Refractory, with Excess of Blasts
30
Primary Myelofibrosis
28
Leukemia, Plasma Cell
23
Waldenstrom Macroglobulinemia
22
Neoplasm, Residual
21
Leukemia, Myeloid, Chronic-Phase
21
Interventions
pembrolizumab
1
Interleukin-15
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Bronchogenic
×
Other hematologic neoplasm
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled